AZD1152 in Patients With Advanced Solid Malignancies-Study 1

• Status: Terminated
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 2-hour infusion every week and every 2 weeks in patients with advanced solid malignancies.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Histological or cytological confirmation of a solid, malignant tumour

• At least measurable or non measurable site of disease as defined by modified RECIST criteria.

Exclusion Criteria:

• Participation in an investigational drug study within 30 days prior to entry or who have not recovered from the effects of an investigational study drug

• Treatment with radiotherapy/chemotherapy with 4 weeks of first dose

• Recent major surgery within 4 weeks prior to entry to the study